The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1003
June 20, 1997
View Complete Issue         Table of Contents 2019 
Cabergoline for Hyperprolactinemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cabergoline for Hyperprolactinemia
June 20, 1997 (Issue: 1003)
Cabergoline (Dostinex - Pharmacia & Upjohn), an ergot alkaloid derivative recently marketed for treatment of hyperprolactinemia, is a selective D2 dopamine agonist that inhibits prolactin-secreting cells in the pituitary. Bromocriptine (Parlodel -...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cabergoline for Hyperprolactinemia
Article code: 1003b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.